DORZOLAMIDE-TIMOLOL SOLUTION

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE); TIMOLOL (TIMOLOL MALEATE)

थमां उपलब्ध:

ALCON CANADA INC

ए.टी.सी कोड:

S01ED51

INN (इंटरनेशनल नाम):

TIMOLOL, COMBINATIONS

डोज़:

2.0%; 0.5%

फार्मास्यूटिकल फॉर्म:

SOLUTION

रचना:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 2.0%; TIMOLOL (TIMOLOL MALEATE) 0.5%

प्रशासन का मार्ग:

OPHTHALMIC

पैकेज में यूनिट:

5ML/10ML

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

BETA-ADRENERGIC AGENTS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0237301001; AHFS:

प्राधिकरण का दर्जा:

CANCELLED PRE MARKET

प्राधिकरण की तारीख:

2021-06-25

उत्पाद विशेषताएं

                                _Product Monograph – _
_ _
_Page 1 of 28_
_ _
_DORZOLAMIDE-TIMOLOL _
_ _
PRODUCT MONOGRAPH
PR
DORZOLAMIDE-TIMOLOL
Dorzolamide (as Dorzolamide Hydrochloride USP) 2.0% and
Timolol (as Timolol Maleate USP) 0.5% w/v
Sterile Ophthalmic Solution
Elevated Intraocular Pressure Therapy
(Topical Carbonic Anhydrase Inhibitor and Topical Beta-Adrenergic
Blocking Agent)
Alcon Canada Inc.
2665 Meadowpine Blvd.
Mississauga, ON
L5N 8C7
Date of Preparation:
October 1, 2010
SUBMISSION CONTROL NO: 131041
_Product Monograph – _
_ _
_Page 2 of 28_
_ _
_DORZOLAMIDE-TIMOLOL _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..................................................... 3
SUMMARY PRODUCT
INFORMATION.........................................................................
3
INDICATIONS AND CLINICAL
USE...............................................................................
3
CONTRAINDICATIONS
.....................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................
4
ADVERSE
REACTIONS......................................................................................................
7
DRUG
INTERACTIONS......................................................................................................
8
DOSAGE AND ADMINISTRATION
...............................................................................
10
OVERDOSAGE
...................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 11
STORAGE AND
STABILITY............................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 14
PART II: SCIENTIFIC INFORMATION
...........................................................................
15
PHARMACEUTICAL
INFORMATIO
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 01-10-2010

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें